Alaunos Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
TCRT$1.67-4.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements
INDEX TO FINANCIAL STATEMENTS
| Page | ||
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 00677) | F-1 | |
|---|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 49) | F-2 | |
| Balance Sheets as of December 31, 2024 and 2023 | F-3 | |
| Statements of Operations for the Years Ended December 31, 2024 and 2023 | F-4 | |
| Statements of Changes in Stockholders’ Equity for the Years Ended December 31, 2024 and 2023 | F-5 | |
| Statements of Cash Flows for the Years Ended December 31, 2024 and 2023 | F-6 | |
| Notes to Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.